← ANALYST RATINGS · TIPRANKS
Monopar Therapeutics Inc (MNPR): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy1 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $130, the highest $145, the lowest $119. The average is +88.2% from the last price of $69.27.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $76.00 → $75.00−1.3% | Hold | +8.3% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $71.00 → $70.00−1.4% | Hold | +1.1% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $72.00 → $71.00−1.4% | Hold | +2.5% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $73.00 → $72.00−1.4% | Hold | +3.9% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $72.00 → $71.00−1.4% | Hold | +2.5% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $70.00 → $69.00−1.4% | Hold | −0.4% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $75.00 → $76.00+1.3% | Hold | +9.7% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $70.00 → $71.00+1.4% | Hold | +2.5% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $71.00 → $72.00+1.4% | Hold | +3.9% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $72.00 → $73.00+1.4% | Hold | +5.4% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $71.00 → $72.00+1.4% | Hold | +3.9% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $69.00 → $70.00+1.4% | Hold | +1.1% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $89.00 → $75.00−15.7% | Hold | +8.3% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $83.00 → $70.00−15.7% | Hold | +1.1% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $84.00 → $71.00−15.5% | Hold | +2.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $86.00 → $72.00−16.3% | Hold | +3.9% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $84.00 → $71.00−15.5% | Hold | +2.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $82.00 → $69.00−15.9% | Hold | −0.4% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $101 → $123+21.8% | Buy | +77.6% | Reiterated | 28.09.26on TipRanks 08:06 | −1.0%next day −4.3% · 5 days −7.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $96.00 → $89.00−7.3% | Hold | +28.5% | Reiterated | 27.09.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $90.00 → $83.00−7.8% | Hold | +19.8% | Reiterated | 27.09.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $92.00 → $84.00−8.7% | Hold | +21.3% | Reiterated | 27.09.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $94.00 → $86.00−8.5% | Hold | +24.2% | Reiterated | 27.09.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $96.00 → $84.00−12.5% | Hold | +21.3% | Reiterated | 27.09.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $96.00 → $82.00−14.6% | Hold | +18.4% | Reiterated | 27.09.26on TipRanks 06:05 | — | |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $125 | Buy | +80.5% | Reiterated | 21.09.26on TipRanks Sep 22 05:45 | −2.3%next day +1.0% · 5 days −11.5% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $128 → $145+13.3% | Buy | +109.3% | Reiterated | 11.09.26on TipRanks 05:15 | −0.6%next day −1.3% · 5 days −12.4% | ↗ |
| Maxwell Skor★★★★★★★★★★#486 · hits 74% · avg +28.0% | Morgan Stanley | $115 → $130+13.0% | Buy | +87.7% | Assigned | 17.08.26on TipRanks 08:55 | +3.5%next day +2.9% · 5 days −3.2% | ↗ |
| Kristen Kluska★★★★★★★★★★#457 · hits 48% · avg +23.3% | Cantor Fitzgerald | $109 → $119+9.2% | Hold | +71.8% | Downgrade | 12.08.26on TipRanks Aug 13 05:25 | +0.1%next day −4.6% · 5 days +8.2% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $130 | Buy | +87.7% | Reiterated | 12.08.26on TipRanks 17:15 | −4.6%next day +2.6% · 5 days +2.4% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $117 → $133+13.7% | Buy | +92.0% | Reiterated | 12.08.26on TipRanks 16:05 | −4.6%next day +2.6% · 5 days +2.4% | ↗ |
| Chad Messer★★★★★★★★★★#9258 · hits 37% · avg −0.2% | Lake Street | $103 | Buy | +48.7% | Reiterated | 30.06.26on TipRanks 09:05 | −2.9%next day +2.8% · 5 days +7.4% | ↗ |
| Unknown Analyst | Leerink Partners | $115 | Buy | +66.0% | Reiterated | 15.05.26on TipRanks 11:35 | −1.6%next day −5.0% · 5 days +5.6% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | $142 → $123−13.4% | Buy | +77.6% | Reiterated | 14.11.25on TipRanks 20:45 | −1.1%next day +6.3% · 5 days +20.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Monopar Therapeutics Inc
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $129 at a price of $79.67 (+62.3%); now: $129 at $69.27 (+86.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 12 | 8 | 2 | 0 | 0 |
| Buy | 0 | 3 | 8 | 13 | 12 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 06.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.82 (from $-1.37 to $-0.37). Last quarter: $-0.62.
Best top-analyst consensus in the sector · Healthcare
About Monopar Therapeutics Inc
- CEO: Chandler D. Robinson
- Employees: 22
- 1000 Skokie Boulevard, Wilmette, IL, 60091, US
- www.monopartx.com
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Data from the stock’s TipRanks forecast page, read 95 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗